• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Redx Pharma, AstraZeneca collaborate

Redx Pharma, AstraZeneca collaborate

September 4, 2014
CenterWatch Staff

Redx Pharma, a U.K.-based group focused on early stage drug discovery and development, has entered into a research collaboration with AstraZeneca to discover and develop new molecules targeting a genetic driver of tumor growth and survival.

The research will complement AZ's strategic approach focused on genetic drivers of cancer and mechanisms of resistance to established and novel cancer therapies.

The research collaboration will involve Redx Pharma scientists working with AZ's oncology innovative medicines group to accelerate the drug discovery process. Redx Pharma will use its early stage drug discovery capabilities to identify novel leads whose further development will be supported by AZ.

Redx Pharma will receive an undisclosed upfront payment. In addition, Redx Pharma is potentially eligible for significant development and commercial milestones, as well as tiered royalties as the program progresses. AZ will have the sole rights to further develop and commercialize any program resulting from the collaboration to add to its portfolio of cancer medicines.

Susan Galbraith, AZ’s head of the oncology innovative medicines unit, said, “This partnership is based on our own early stage oncology research focused on the genetic drivers of cancer and allows us to build on our combined drug discovery expertise.”

Redx Pharma was one of the first tenants at the BioHub at Alderley Park in Cheshire, set up by AZ in 2013 to allow life sciences companies to benefit from Alderley Park's scientific heritage and state-of-the-art research facilities. AZ and Redx scientists will work together at Alderley Park, as well as at Redx's Liverpool facility where the project will be based.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing